PROGLYCEM (diazoxide)
VASODILATORS·INSULINOMA·+2
Teva Pharmaceuticals USA
Indication
Nesidioblastosis
Nesidioblastosis is a rare endocrine pancreatic condition characterized by the abnormal neoformation, hyperplasia, and functional dysregulation of insulin-secreting beta cells originating from the pancreatic ductal epithelium. Read more about Nesidioblastosis
3 drugs 3 manufacturers
Drugs that treat it
Common Nesidioblastosis therapies.
Filter & compare in the drug finder →Opens the drug finder with Nesidioblastosis preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonNesidioblastosis is a rare endocrine pancreatic condition characterized by the abnormal neoformation, hyperplasia, and functional dysregulation of insulin-secreting beta cells originating from the pancreatic ductal epithelium.
It affects the endocrine system across pediatric populations—where it classically underlies persistent congenital hyperinsulinism in infants—and less commonly presents in adults either idiopathically or secondary to bariatric procedures such as Roux-en-Y gastric bypass.
Histopathologically defined by enlarged, pleomorphic beta-cell clusters and ductuloinsular complexes, the disorder can occur in focal or diffuse distributions throughout the pancreas.
Clinically, it manifests as persistent endogenous hyperinsulinemic hypoglycemia, resulting in neuroglycopenic symptoms and autonomic distress in the absence of a localized insulinoma.
- nih.gov
Nesidioblastosis is a rare endocrine pancreatic condition characterized by the abnormal neoformation, hyperplasia, and functional dysregulation of insulin-secreting beta cells originating from the pancreatic ductal epithelium
- nih.gov
Nesidioblastosis is a rare endocrine pancreatic condition characterized by the abnormal neoformation, hyperplasia, and functional dysregulation of insulin-secreting beta cells originating from the pancreatic ductal epithelium
- nih.gov
It affects the endocrine system across pediatric populations—where it classically underlies persistent congenital hyperinsulinism in infants—and less commonly presents in adults either idiopathically or secondary to bariatric procedures such as Roux-en-Y gastric bypass Histopathologically defined by enlarged, pleomorphic beta-cell clusters and ductuloinsular complexes, the disorder can occur in focal or diffuse distributions throughout the pancreas
- nih.gov
It affects the endocrine system across pediatric populations—where it classically underlies persistent congenital hyperinsulinism in infants—and less commonly presents in adults either idiopathically or secondary to bariatric procedures such as Roux-en-Y gastric bypass
- nih.gov
It affects the endocrine system across pediatric populations—where it classically underlies persistent congenital hyperinsulinism in infants—and less commonly presents in adults either idiopathically or secondary to bariatric procedures such as Roux-en-Y gastric bypass
- nih.gov
Histopathologically defined by enlarged, pleomorphic beta-cell clusters and ductuloinsular complexes, the disorder can occur in focal or diffuse distributions throughout the pancreas Clinically, it manifests as persistent endogenous hyperinsulinemic hypoglycemia, resulting in neuroglycopenic symptoms and autonomic distress in the absence of a localized insulinoma
- nih.gov
Clinically, it manifests as persistent endogenous hyperinsulinemic hypoglycemia, resulting in neuroglycopenic symptoms and autonomic distress in the absence of a localized insulinoma
- wjgnet.com
Clinically, it manifests as persistent endogenous hyperinsulinemic hypoglycemia, resulting in neuroglycopenic symptoms and autonomic distress in the absence of a localized insulinoma
Personalize your experience
Follow Nesidioblastosis and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.